Patents Examined by Michael Burkhart
  • Patent number: 10131876
    Abstract: The present invention provides a process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and/or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and/or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: November 20, 2018
    Assignee: Miltenyi Biotec GmbH
    Inventors: Andrew Kaiser, Mario Assenmacher, Ian Johnston
  • Patent number: 10059936
    Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: August 28, 2018
    Assignee: Dyax Corp.
    Inventors: Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Patent number: 10045953
    Abstract: A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: August 14, 2018
    Assignees: Case Western Reserve University, The Penn State Research Foundation
    Inventors: Eric Pearlman, Mark Kester
  • Patent number: 10046066
    Abstract: Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: August 14, 2018
    Inventors: Jun Gao, Eric Hsu, Anthony Cheung
  • Patent number: 10035829
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 31, 2018
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Patent number: 9987308
    Abstract: The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific CD8+ T cells in the presence of tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment a CD8+ T cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific CD8+ T cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: June 5, 2018
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. Riddell, Michael Hudecek
  • Patent number: 9969813
    Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: May 15, 2018
    Assignee: BIOATLA, LLC
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
  • Patent number: 9963511
    Abstract: Herein is reported an expression vector comprising—an antibody light chain expression cassette, —an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5? to 3? sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 8, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Peter Michael Huelsmann, Hendrik Knoetgen
  • Patent number: 9957328
    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 1, 2018
    Assignee: UCB PHARMA, S.A.
    Inventors: Mark Ellis, David Paul Humphreys
  • Patent number: 9914929
    Abstract: Methods of generating fusion protein variants are provided that comprise introducing sequence diversity at the junction region or regions in the fusion and allows for the generation of variants having a desired activity. Examples include immunoglobulins comprising a domain or polypeptide inserted into, or replacing, a CDR. Also provided are polynucleotides encoding a fusion protein and comprising two or more RSSs, and compositions and host cells comprising same, as well as fusion proteins variants produced by the described methods.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 13, 2018
    Assignee: Innovative Targeting Solutions Inc.
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott
  • Patent number: 9901639
    Abstract: The present invention provides an isolated population of bone marrow-derived endothelial progenitor cells (EPCs) and uses thereof for the treatment of vascular diseases.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 27, 2018
    Assignee: Temple University—of the Commonwealth System of Higher Education
    Inventor: Hong Wang
  • Patent number: 9889164
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 13, 2018
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Patent number: 9862779
    Abstract: Herein is reported a method for producing a polypeptide comprising at least two polypeptide domains comprising the step of cultivating a cell comprising (a) a nucleic acid encoding a soluble S. aureus sortase A with a C-terminal endoplasmic reticulum retention signal, (b) a nucleic acid encoding a first polypeptide domain comprising at its C-terminus a sortase motif followed by an endoplasmic reticulum retention signal, and (c) a nucleic acid encoding a second polypeptide domain comprising at its N-terminus at least a diglycine, whereby the cell secretes the sortase A conjugate of the first polypeptide domain and the second polypeptide domain, thereby producing a polypeptide comprising at least two polypeptide domains.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 9, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Mariel Beck, Georg Tiefenthaler
  • Patent number: 9850482
    Abstract: A heterologous DNA barcoding method is provided. The method includes (a) providing a DNA microarray having DNA oligonucleotide spots, which are distinguished from each other by their barcode sequences, (b) providing a microwell array having microwells whose spatial arrangement corresponds to that of the DNA spots on the DNA microarray, (c) loading a solution of samples containing target nucleic acid sequences into the microwells, (d) assembling the DNA microarray to the microwell array to form micro reaction spaces in which the DNA spots are spatially separated by the microwells, (e) allowing the oligonucleotide sequences of the DNA spots to react with the target nucleic acid sequences of the samples in the micro reaction spaces to combine the sequence information of the DNA spots with the sequence information of the samples, and (f) separating the DNA microarray and the microwell array from each other to obtain reaction products including the barcode sequences.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: December 26, 2017
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Sunghoon Kwon, Junhoi Kim, Taehoon Ryu, Dongyoon Oh, Jaekyung Koh
  • Patent number: 9849092
    Abstract: A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy. With respect to gene delivery, the inventive method may be used in cancer therapy, but is not limited to such use; it will be appreciated that the inventive method may be used for gene delivery in general. The controlled and precise application of thermal energy enhances gene transfer to any cell, whether the cell is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: December 26, 2017
    Inventor: Gholam A. Peyman
  • Patent number: 9833479
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted integration of a functional SCID-related genes (e.g., IL2RG, RAG1 and/or RAG2 gene) into the genome of a cell for provision of proteins lacking or deficient in SCID.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: December 5, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Michael C. Holmes, Fyodor Urnov
  • Patent number: 9822342
    Abstract: The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 21, 2017
    Assignee: KYOTO UNIVERSITY
    Inventors: Shinya Yamanaka, Yoshinori Yoshida, Kenji Miki
  • Patent number: 9807987
    Abstract: There are provided to a Rag-2 (Recombination activating gene 2) gene targeting vector, a method for producing SCID-like miniature pigs introduced with the vector, and a use thereof.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 7, 2017
    Assignees: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP., THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Jin-Hoi Kim, Deug-Nam Kwon, Randall S. Prather, Kiho Lee
  • Patent number: 9803216
    Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 31, 2017
    Assignee: University of Maryland
    Inventors: Elankumaran Subbiah, Siba K. Samal
  • Patent number: 9783821
    Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 10, 2017
    Assignee: RIKEN
    Inventors: Shin-ichiro Fujii, Kanako Shimizu, Jun Shinga